Press releases
-
-
-
-
Internal link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2
-
Internal link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
-
Internal link ProQR to Present at Cowen Health Care Conference
-
-
-
-
Internal link ProQR to Host R&D Day in New York on January 29
-
-
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index
-
Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10
-
Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10
-
-
Internal link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10
-
Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
-
-
-
Internal link ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference
-
Internal link ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten für die Augenheilkunde von Ionis Pharmaceuticals
-
Internal link ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals
-
-
Internal link ProQR Announces Presentations at the OTS Annual Meeting
-